Ceryvyn Therapeutics Limited (ASX: CYV)
Health Care · Biotechnology · AU
AU$0.01
-8.33% today · -31.3% 1Y
Ceryvyn Therapeutics Limited (ASX: CYV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.79M and employs 10 people.
Over the last twelve months the share price has lost 31.3%, trading between 0.01 and 0.03.
Tweenvest scores Ceryvyn Therapeutics Limited across four factors: quality 25/100, value 41/100, growth 74/100. Its strongest factor is growth.
CYV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.79M
- Revenue (TTM)
- $-13.42K
- P/E
- 0.05
- EPS
- 0.23
- Dividend yield
- —
- Beta (5Y)
- 1.50
- 52-week high
- AU$0.03
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 1.37B
- Employees
- 10
- Next earnings
- —
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
- ISIN
- AU0000478117
- Founded
- 1984
- Listed since
- Jun 30, 2026
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.